Jae Hoon Lee
About
Jae Hoon Lee is a scholar working on Hematology, Oncology and Molecular Biology.
According to data from OpenAlex, Jae Hoon Lee has authored 162 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Hematology, 73 papers in Oncology and 58 papers in Molecular Biology. Recurrent topics in Jae Hoon Lee's work include Multiple Myeloma Research and Treatments (81 papers), Protein Degradation and Inhibitors (35 papers) and Cancer Treatment and Pharmacology (26 papers). Jae Hoon Lee is often cited by papers focused on Multiple Myeloma Research and Treatments (81 papers), Protein Degradation and Inhibitors (35 papers) and Cancer Treatment and Pharmacology (26 papers). Jae Hoon Lee collaborates with scholars based in South Korea, United States and Spain. Jae Hoon Lee's co-authors include Dong Bok Shin, Eun Kyung Cho, Soo‐Mee Bang, Junshik Hong, Jinny Park, Se Hoon Park, Cheolwon Suh, Kihyun Kım, Sun Jin Sym and Sung‐Soo Yoon and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Jae Hoon Lee
156 papers receiving 2.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jae Hoon Lee South Korea | 27 | 1.2k | 1.0k | 851 | 570 | 562 | 162 | 2.4k | ||
| Ulrich Mey Germany | 25 | 854 0.7× | 1.5k 1.5× | 653 0.8× | 769 1.3× | 1.0k 1.8× | 68 | 2.9k | ||
| Hannes Wandt Germany | 22 | 1.0k 0.9× | 1.1k 1.1× | 359 0.4× | 785 1.4× | 1.2k 2.1× | 57 | 2.6k | ||
| Joon Ho Moon South Korea | 24 | 807 0.7× | 561 0.5× | 655 0.8× | 282 0.5× | 391 0.7× | 175 | 1.9k | ||
| Chul Won Choi South Korea | 28 | 628 0.5× | 851 0.8× | 487 0.6× | 457 0.8× | 664 1.2× | 192 | 2.8k | ||
| Yeung‐Chul Mun South Korea | 22 | 634 0.6× | 647 0.6× | 422 0.5× | 340 0.6× | 455 0.8× | 149 | 1.8k | ||
| Rachid Baz United States | 32 | 2.3k 2.0× | 1.6k 1.6× | 2.1k 2.5× | 595 1.0× | 335 0.6× | 183 | 3.7k | ||
| Stephen J. Noga United States | 24 | 1.2k 1.1× | 1.1k 1.1× | 795 0.9× | 260 0.5× | 208 0.4× | 82 | 2.4k | ||
| Yago Nieto United States | 34 | 1.9k 1.6× | 1.7k 1.7× | 859 1.0× | 644 1.1× | 594 1.1× | 242 | 4.0k | ||
| William J. Edenfield United States | 19 | 661 0.6× | 783 0.8× | 674 0.8× | 394 0.7× | 179 0.3× | 101 | 2.1k | ||
| Frédéric Maloisel France | 29 | 1.6k 1.3× | 877 0.9× | 848 1.0× | 626 1.1× | 484 0.9× | 74 | 2.8k |
Countries citing papers authored by Jae Hoon Lee
Since
Specialization
Citations
This map shows the geographic impact of Jae Hoon Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jae Hoon Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jae Hoon Lee more than expected).
Fields of papers citing papers by Jae Hoon Lee
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jae Hoon Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jae Hoon Lee. The network helps show where Jae Hoon Lee may publish in the future.
Co-authorship network of co-authors of Jae Hoon Lee
This figure shows the co-authorship network connecting the top 25 collaborators of Jae Hoon Lee. A scholar is included among the top collaborators of Jae Hoon Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jae Hoon Lee. Jae Hoon Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kim, Jin Seok, Jun Ho Jang, Deog‐Yeon Jo, et al.. (2023). Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea. Journal of Korean Medical Science. 38(41). e328–e328.
2.
Kim, Mihee, Je‐Jung Lee, Chang‐Ki Min, et al.. (2023). Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015). Annals of Hematology. 102(8). 2233–2240.
3.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2022). Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. HemaSphere. 6(12). e801–e801.
4.
Jung, Sung‐Hoon, Kihyun Kım, Jae Hoon Lee, et al.. (2022). Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma. Annals of Hematology. 101(6). 1217–1226.
5.
Jung, Sung‐Hoon, Kihyun Kım, Sang Eun Yoon, et al.. (2022). Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party. Blood Cancer Journal. 12(11). 157–157.
6.
Yoo, Kwai Han, So Hyun Park, So Hyun Park, et al.. (2022). Low-dose abdominopelvic computed tomography in patients with lymphoma: An image quality and radiation dose reduction study. PLoS ONE. 17(8). e0272356–e0272356.
7.
Yoo, Kwai Han, Dok Hyun Yoon, Hye Jin Kang, et al.. (2021). Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features. Current Problems in Cancer. 46(1). 100788–100788.
8.
Jurczak, Wojciech, Andrzej Pluta, Małgorzata Wach, et al.. (2021). Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 138(Supplement 1). 393–393.
9.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2020). ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 38(25). 2849–2861.
10.
Byun, Ja Min, Junshik Hong, Doyeun Oh, et al.. (2020). Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in Adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but Not Acute Myeloid Leukemia. Journal of Clinical Medicine. 9(7). 2310–2310.
11.
Jung, Sung‐Hoon, Je‐Jung Lee, Je‐Jung Lee, et al.. (2018). Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). Biology of Blood and Marrow Transplantation. 24(5). 923–929.
12.
Kim, Young Saing, Eun Kyung Cho, Junshik Hong, et al.. (2015). Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment. 48(1). 80–87.
13.
Lu, Jin, Jae Hoon Lee, Jae Hoon Lee, et al.. (2015). Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial. Blood. 126(23). 4240–4240.
14.
Kım, Kihyun, Dok Hyun Yoon, Jin Seok Kim, et al.. (2014). Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea. BioMed Research International. 2014. 1–7.
15.
Lee, Jong Wook, Jun Ho Jang, Je‐Hwan Lee, et al.. (2014). Ineffective Corticosteroid Treatment for Hemolysis Management of Paroxysmal Nocturnal Hemoglobinuria. Blood. 124(21). 5151–5151.
16.
Baz, Rachid, Hui‐Yi Lin, Sung‐Soo Yoon, et al.. (2013). Response Adapted Lenalidomide Based Therapy For Newly Diagnosed (ND) Standard Risk Older Adults With Multiple Myeloma (MM): An International Collaboration. Blood. 122(21). 3201–3201.
17.
Lee, Jae Hoon & Keum Ha Choi. (2013). A Case of Multiple Extramedullary Plasmacytoma Arising from the Nasal Cavity, Nasal Septum, and Nasopharynx in a Patient with Nasal Polyps. Journal of rhinology. 20(1). 58–61.
18.
Lee, Jong Wook, Jun Ho Jang, Je‐Hwan Lee, et al.. (2013). Clinical Signs and Symptoms In Non-Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria From a Korean Prospective PNH Registry. Blood. 122(21). 3720–3720.
19.
Kim, Seok Jin, Hyo Jin Lee, Hawk Kim, et al.. (2007). Varicella Zoster Virus Reactivation with the Use of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients.. Blood. 110(11). 4843–4843.
20.
Lee, Keun‐Wook, Tak Yun, Im Il Na, et al.. (2005). A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma. Journal of Korean Medical Science. 20(4). 598–598.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ulrich Mey Breakdown of academic impact, for papers by Hannes Wandt Breakdown of academic impact, for papers by Joon Ho Moon Breakdown of academic impact, for papers by Chul Won Choi Breakdown of academic impact, for papers by Yeung‐Chul Mun Breakdown of academic impact, for papers by Rachid Baz Breakdown of academic impact, for papers by Stephen J. Noga Breakdown of academic impact, for papers by Yago Nieto Breakdown of academic impact, for papers by William J. Edenfield Breakdown of academic impact, for papers by Frédéric Maloisel